HK1197176A1 - Topical ophthalmological pharmaceutical composition containing regorafenib - Google Patents

Topical ophthalmological pharmaceutical composition containing regorafenib Download PDF

Info

Publication number: HK1197176A1
Authority: HK; Hong Kong
Prior art keywords: pharmaceutical composition; regorafenib; pharmaceutically acceptable; retinal; active agent
Prior art date: 2011-06-28

Application number

HK14110517.7A

Other languages

English (en)

Chinese (zh)

Inventor

Michael BÖTTGER

Georges Von Degenfeld

Julia FREUNDLIEB

Claudia Hirth-Dietrich

Joerg Keldenich

Jürgen KLAR

Uwe Muenster

Andreas Ohm

Annett Richter

Bernd Riedl

Original Assignee

Bayer Healthcare Llc

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2011-06-28

Filing date

2012-06-26

Publication date

2015-01-09

Family has litigation

First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=46456546&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=HK1197176(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.

2012-06-26 Application filed by Bayer Healthcare Llc filed Critical Bayer Healthcare Llc

2015-01-09 Publication of HK1197176A1 publication Critical patent/HK1197176A1/xx

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4412—Non condensed pyridines; Hydrogenated derivatives thereof having oxo groups directly attached to the heterocyclic ring
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/02—Inorganic compounds
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/14—Esters of carboxylic acids, e.g. fatty acid monoglycerides, medium-chain triglycerides, parabens or PEG fatty acid esters
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0048—Eye, e.g. artificial tears
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/10—Dispersions; Emulsions
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A61P27/06—Antiglaucoma agents or miotics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A61P27/12—Ophthalmic agents for cataracts

Landscapes

Health & Medical Sciences (AREA)
Chemical & Material Sciences (AREA)
Public Health (AREA)
Veterinary Medicine (AREA)
Medicinal Chemistry (AREA)
Pharmacology & Pharmacy (AREA)
Life Sciences & Earth Sciences (AREA)
Animal Behavior & Ethology (AREA)
General Health & Medical Sciences (AREA)
Epidemiology (AREA)
Engineering & Computer Science (AREA)
Chemical Kinetics & Catalysis (AREA)
General Chemical & Material Sciences (AREA)
Ophthalmology & Optometry (AREA)
Oil, Petroleum & Natural Gas (AREA)
Bioinformatics & Cheminformatics (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Organic Chemistry (AREA)
Inorganic Chemistry (AREA)
Dispersion Chemistry (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Medicinal Preparation (AREA)

HK14110517.7A 2011-06-28 2012-06-26 Topical ophthalmological pharmaceutical composition containing regorafenib HK1197176A1 (en)

Applications Claiming Priority (5)

Application Number	Priority Date	Filing Date	Title
EP11171719.5		2011-06-28
EP11171719		2011-06-28
EP12155281.4		2012-02-14
EP12155281		2012-02-14
PCT/EP2012/062365 WO2013000917A1 (fr)	2011-06-28	2012-06-26	Composition pharmaceutique topique ophtalmologique contenant du régorafénib

Publications (1)

Publication Number	Publication Date
HK1197176A1 true HK1197176A1 (en)	2015-01-09

Family

ID=46456546

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
HK14110517.7A HK1197176A1 (en)	2011-06-28	2012-06-26	Topical ophthalmological pharmaceutical composition containing regorafenib

Country Status (26)

Country	Link
US (1)	US20140296301A1 (fr)
EP (1)	EP2726059A1 (fr)
JP (1)	JP5998213B2 (fr)
KR (1)	KR20140048218A (fr)
CN (1)	CN103889399A (fr)
AP (1)	AP2013007335A0 (fr)
AR (1)	AR086800A1 (fr)
AU (1)	AU2012277905A1 (fr)
BR (1)	BR112013033831A2 (fr)
CA (1)	CA2840329A1 (fr)
CL (1)	CL2013003700A1 (fr)
CO (1)	CO6920289A2 (fr)
CR (1)	CR20130693A (fr)
CU (1)	CU24163B1 (fr)
DO (1)	DOP2013000314A (fr)
EA (1)	EA201400064A1 (fr)
EC (1)	ECSP13013106A (fr)
GT (1)	GT201300322A (fr)
HK (1)	HK1197176A1 (fr)
MX (1)	MX2013015287A (fr)
PE (1)	PE20141031A1 (fr)
PH (1)	PH12013502691A1 (fr)
TN (1)	TN2013000533A1 (fr)
UY (1)	UY34166A (fr)
WO (1)	WO2013000917A1 (fr)
ZA (1)	ZA201400646B (fr)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
KR101239489B1 (ko)	2004-09-29	2013-03-06	바이엘 파마 악티엔게젤샤프트	열역학적으로 안정한 형태의 ｂａｙ 43-9006 토실레이트
AR081060A1 (es)	2010-04-15	2012-06-06	Bayer Schering Pharma Ag	Procedimiento para preparar 4-{4-[({[4-cloro-3-(trifluorometil)fenil]amino}carbonil)amino]-3-fluorofenoxi}-n-metilpiridin-2-carboxamida
UY35183A (es) *	2012-12-21	2014-07-31	Bayer Healthcare Llc	Composición farmacéutica oftalmológica tópica que contiene regorafenib
WO2015011659A1 (fr) *	2013-07-24	2015-01-29	Dr. Reddys Laboratories Limited	Formes polymorphes cristallines du régorafénib et méthodes de préparation de la forme polymorphe i du régorafénib
CN103923000A (zh) *	2014-01-29	2014-07-16	苏州晶云药物科技有限公司	几种新晶型及其制备方法
CN104546776B (zh) *	2015-02-10	2017-08-22	杭州朱养心药业有限公司	瑞戈非尼片剂药物组合物和制法
KR20240034866A (ko) *	2015-06-06	2024-03-14	클라우드브레이크 테라퓨틱스, 엘엘씨	익상편을 치료하기 위한 조성물 및 방법
WO2017210132A1 (fr)	2016-06-02	2017-12-07	Cloudbreak Therapeutics, Llc	Compositions et méthodes d'utilisation de nintédanib pour le traitement de maladies oculaires à néovascularisation anormale

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
FR2732222B1 (fr) *	1995-03-28	1997-04-25	Oreal	Utilisation d'un antagoniste de cgrp pour le traitement des prurits et des dysesthesies oculaires et palpebraux
DK2020243T3 (en) *	2002-05-28	2018-11-19	Astrazeneca Ab	Pharmaceutical composition which can be applied topically
NZ544920A (en)	2003-07-23	2009-11-27	Bayer Healthcare Llc	4{4-[3-(4-chloro-3-trifluoromethylphenyl)-ureido]-3-fluorophenoxy}-pyridine-2-carboxylic acid methylamide and metabolites for the treatment and prevention of diseases and conditions
CA2607608A1 (fr)	2005-05-10	2006-11-16	Alcon, Inc.	Formulations de suspension de nepafenac et d'autres medicaments ophtalmiques pour le traitement topique des troubles ophtalmiques
BRPI0606172A2 (pt)	2005-06-08	2009-06-02	Targegen Inc	métodos e composições para o tratamento de distúrbios oculares
UA94427C2 (ru)	2005-11-29	2011-05-10	Смиткляйн Бичам Корпорейшн	Фармацевтическая композиция для местного лечения неоваскулярных расстройств глаз
WO2007068382A1 (fr) *	2005-12-15	2007-06-21	Bayer Healthcare Ag	Diaryle-uree pour le traitement de maladies inflammatoires de la peau, l'oeil et/ou l'oreille
EP1962803A1 (fr)	2005-12-23	2008-09-03	Alcon, Inc.	Preparation pharmaceutique pour l'administration de composes recepteurs inhibiteurs de la tyrosine kinase (rtki) dans l'oeil
WO2008027341A2 (fr)	2006-08-30	2008-03-06	Merck & Co., Inc.	Formulations ophtalmiques locales
AR062927A1 (es) *	2006-10-11	2008-12-17	Bayer Healthcare Ag	4- [4-( [ [ 4- cloro-3-( trifluorometil) fenil) carbamoil] amino] -3- fluorofenoxi) -n- metilpiridin-2- carboxamida monohidratada
EP2156833B1 (fr) *	2007-05-11	2011-11-30	Santen Pharmaceutical Co., Ltd	Agent prophylactique ou thérapeutique destiné à une maladie oculaire postérieure comprenant un agoniste qui n'est pas dérivé de l'ergot de seigle sélectif du récepteur d2 en tant que principe actif
DE102007055341A1 (de) *	2007-11-19	2009-05-20	Bayer Animal Health Gmbh	Stabilisierung öliger Suspensionen enthaltend hydrophobe Kieselsäuren
JP2012525415A (ja)	2009-05-01	2012-10-22	オプソテツク・コーポレイシヨン	眼科疾患を処置または予防するための方法
JP2012533562A (ja)	2009-07-16	2012-12-27	グラクソウェルカムマニュファクチュアリングピーティーイーリミテッド	治療法

2012
- 2012-06-26 WO PCT/EP2012/062365 patent/WO2013000917A1/fr not_active Ceased
- 2012-06-26 PE PE2013002872A patent/PE20141031A1/es not_active Application Discontinuation
- 2012-06-26 BR BR112013033831A patent/BR112013033831A2/pt not_active IP Right Cessation
- 2012-06-26 PH PH1/2013/502691A patent/PH12013502691A1/en unknown
- 2012-06-26 CN CN201280042504.9A patent/CN103889399A/zh active Pending
- 2012-06-26 AP AP2013007335A patent/AP2013007335A0/xx unknown
- 2012-06-26 CA CA2840329A patent/CA2840329A1/fr not_active Abandoned
- 2012-06-26 HK HK14110517.7A patent/HK1197176A1/xx unknown
- 2012-06-26 JP JP2014517661A patent/JP5998213B2/ja not_active Expired - Fee Related
- 2012-06-26 US US14/128,356 patent/US20140296301A1/en not_active Abandoned
- 2012-06-26 MX MX2013015287A patent/MX2013015287A/es not_active Application Discontinuation
- 2012-06-26 EP EP12731396.3A patent/EP2726059A1/fr not_active Withdrawn
- 2012-06-26 AU AU2012277905A patent/AU2012277905A1/en not_active Abandoned
- 2012-06-26 EA EA201400064A patent/EA201400064A1/ru unknown
- 2012-06-26 KR KR1020147002095A patent/KR20140048218A/ko not_active Withdrawn
- 2012-06-26 CU CU20130168A patent/CU24163B1/es active IP Right Grant
- 2012-06-27 UY UY0001034166A patent/UY34166A/es not_active Application Discontinuation
- 2012-06-28 AR ARP120102339A patent/AR086800A1/es unknown
2013
- 2013-12-20 CR CR20130693A patent/CR20130693A/es unknown
- 2013-12-23 GT GT201300322A patent/GT201300322A/es unknown
- 2013-12-23 CL CL2013003700A patent/CL2013003700A1/es unknown
- 2013-12-24 EC EC2013013106A patent/ECSP13013106A/es unknown
- 2013-12-26 DO DO2013000314A patent/DOP2013000314A/es unknown
- 2013-12-26 CO CO13300167A patent/CO6920289A2/es not_active Application Discontinuation
- 2013-12-27 TN TNP2013000533A patent/TN2013000533A1/fr unknown
2014
- 2014-01-27 ZA ZA2014/00646A patent/ZA201400646B/en unknown

Also Published As

Publication number	Publication date
KR20140048218A (ko)	2014-04-23
US20140296301A1 (en)	2014-10-02
DOP2013000314A (es)	2014-04-15
AU2012277905A8 (en)	2014-01-30
PE20141031A1 (es)	2014-08-21
EA201400064A1 (ru)	2014-05-30
AR086800A1 (es)	2014-01-22
BR112013033831A2 (pt)	2017-02-14
UY34166A (es)	2013-01-31
NZ619229A (en)	2016-04-29
PH12013502691A1 (en)	2017-08-23
ZA201400646B (en)	2015-11-25
EP2726059A1 (fr)	2014-05-07
TN2013000533A1 (en)	2015-03-30
CA2840329A1 (fr)	2013-01-03
CN103889399A (zh)	2014-06-25
MX2013015287A (es)	2014-03-31
WO2013000917A1 (fr)	2013-01-03
JP2014518233A (ja)	2014-07-28
JP5998213B2 (ja)	2016-09-28
AU2012277905A1 (en)	2014-01-16
CU24163B1 (es)	2016-03-31
CU20130168A7 (es)	2014-04-24
CO6920289A2 (es)	2014-04-10
AP2013007335A0 (en)	2013-12-31
CR20130693A (es)	2016-05-02
GT201300322A (es)	2014-11-13
ECSP13013106A (es)	2014-01-31
CL2013003700A1 (es)	2014-07-18

Publication	Publication Date	Title
HK1204564A1 (en)	2015-11-27	Topical ophthalmological pharmaceutical composition containing axitinib
WO2013000909A1 (fr)	2013-01-03	Composition pharmaceutique topique ophtalmologique contenant du sorafénib
CN104582685A (zh)	2015-04-29	含有舒尼替尼的局部眼科药物组合物
JP5998213B2 (ja)	2016-09-28	レゴラフェニブを含有する眼科用局所医薬組成物
HK1204563A1 (en)	2015-11-27	Topical ophthalmological pharmaceutical composition containing pazopanib
US20150328145A1 (en)	2015-11-19	Topical ophthalmological pharmaceutical composition containing regorafenib
HK1204289A1 (en)	2015-11-13	Topical ophthalmological pharmaceutical composition containing cediranib
TW201313230A (zh)	2013-04-01	包含雷格拉非尼（ｒｅｇｏｒａｆｅｎｉｂ）的局部眼科醫藥組成物
NZ619229B2 (en)	2016-08-02	Topical ophthalmological pharmaceutical composition containing regorafenib
HK1197365A (en)	2015-01-16	Topical ophthalmological pharmaceutical composition containing sorafenib